Valuation: Foresee Pharmaceuticals Co., Ltd.

Market Cap 12.52B 388M 335M 313M 287M 541M 36.91B 549M 3.68B 1.44B 18.5B 1.46B 1.42B 61.16B P/E 2024
-9.84x
P/E 2025 -14.1x
Enterprise Value 12.28B 380M 329M 307M 282M 530M 36.18B 538M 3.6B 1.41B 18.13B 1.43B 1.4B 59.95B EV / Sales 2024
26x
EV / Sales 2025 28.9x
Free-Float
47.69%
Yield 2024 *
-
Yield 2025 -
07-09 Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026 CI
06-08 Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial CI
05-27 Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty CI
05-14 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-13 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-06 Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union CI
02-04 Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty CI
12-24 Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate CI
11-13 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
29/08/25 Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer CI
12/08/25 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
31/07/25 Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive TWD 400 million in funding CI
17/06/25 Foresee Completes Phase 3 CASPPIAN Trial Enrollment For Central Precocious Puberty RE
1 day-0.25%
1 week+0.38%
Current month+0.38%
1 month-6.36%
3 months-0.25%
6 months-8.62%
Current year-1.36%
1 week 78
Extreme 78
80
1 month 76.7
Extreme 76.7
84
Current year 75.1
Extreme 75.1
88.3
1 year 71.9
Extreme 71.9
93.7
3 years 57.7
Extreme 57.7
107.5
5 years 57.7
Extreme 57.7
141
10 years 35.1
Extreme 35.1
141
Manager TitleAgeSince
Chief Executive Officer - 08/02/2013
Chief Tech/Sci/R&D Officer - 09/07/2015
Director of Finance/CFO 58 07/10/2019
Director TitleAgeSince
Director/Board Member - 10/01/2013
Director/Board Member - 10/01/2013
Director/Board Member 75 03/08/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%+0.38%+0.25%-2.33% 388M
+0.99%+1.78%+4.07%+16.73% 49.47B
+3.71%+9.40%+486.98%+592.14% 43.61B
+2.70%+1.57%+33.39%+8.85% 39.29B
+5.60%+10.21%+16.76%+85.72% 39.6B
+2.21%+6.75%+21.31%+53.37% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+37.75%+126.84% 16.49B
-0.11%+2.41%+6.24%+18.87% 14.01B
+0.75%+15.04%+78.59%+30.30% 12.77B
Average +1.88%+5.69%+76.15%+103.39% 26.49B
Weighted average by Cap. +2.54%+6.09%+104.09%+140.56%

Financials

2024 2025
Net sales 419M 12.96M 11.21M 10.47M 9.61M 18.07M 1.23B 18.36M 123M 48.23M 618M 48.69M 47.62M 2.04B 431M 13.35M 11.55M 10.79M 9.9M 18.61M 1.27B 18.91M 127M 49.68M 637M 50.15M 49.05M 2.11B
Net income -1.08B -33.48M -28.96M -27.04M -24.81M -46.66M -3.19B -47.4M -317M -125M -1.6B -126M -123M -5.28B -883M -27.35M -23.66M -22.09M -20.26M -38.12M -2.6B -38.72M -259M -102M -1.3B -103M -100M -4.31B
Net Debt -1.11B -34.28M -29.65M -27.69M -25.4M -47.78M -3.26B -48.53M -325M -128M -1.64B -129M -126M -5.41B -248M -7.67M -6.64M -6.2M -5.69M -10.69M -730M -10.86M -72.72M -28.54M -366M -28.81M -28.18M -1.21B
Logo Foresee Pharmaceuticals Co., Ltd.
Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.
Employees
-
Date Price Change Volume
07/08/26 NT$79.50 -0.25% 66,444
06/08/26 NT$79.70 0.00% 65,343
05/08/26 NT$79.70 +0.63% 33,758
04/08/26 NT$79.20 -0.38% 43,279
03/08/26 NT$79.50 +0.38% 82,476
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
79.50TWD
Average target price
153.00TWD
Spread / Average Target
+92.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 6576 Stock